Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 47Carcinoma, Non-Small-Cell Lung 30Pancreatic Neoplasms 24Ovarian Neoplasms 23Fallopian Tube Neoplasms 21Triple Negative Breast Neoplasms 15Breast Neoplasms, Male 14Brenner Tumor 12Melanoma 10Carcinoma, Ovarian Epithelial 10Unspecified Adult Solid Tumor, Protocol Specific 8Lung Neoplasms 8Uterine Cervical Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Adenocarcinoma of Lung 7Urinary Bladder Neoplasms 6Neoplasms 6Adenocarcinoma, Bronchiolo-Alveolar 6Neoplasm Metastasis 5Stomach Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Cholangiocarcinoma 4Pleural Effusion, Malignant 3Inflammatory Breast Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Transitional Cell 3Uveal Melanoma 2Tongue Neoplasms 2Thymoma 2

Interventions

Gemcitabine 7Leucovorin 6Irinotecan 6Fluorouracil 6130-nm albumin-bound paclitaxel 6Albumin-Bound Paclitaxel 5napabucasin 4Capecitabine 4Paclitaxel 3Oxaliplatin 3Ocoxin 3Bevacizumab 3pembrolizumab 2entinostat 2Sorafenib 2Imatinib Mesylate 2Everolimus 2Cyclophosphamide 2Cisplatin 2Cetuximab 25,10-methylenetetrahydrofolic acid 2tislelizumab 1spartalizumab 1pralsetinib 1palbociclib 1irinotecan sucrosofate 1halofantrine 1guadecitabine 1fludarabine 1ficlatuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Digestive System Neoplasms × Taxes × Clear all
NCT02231723 2023-11-18

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
139 enrolled
Gastrointestinal

Pancreatic cancer, adult, Digestive System Neoplasms, Endocrine Gland Neoplasms, Adenoma, Islet Cell, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Islet Cell, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡